Since the aim of this work was to investigate the therapeutic potential of a selective A2AR antagonist for the treatment of diabetic retinopathy, we wanted to start the intravitreal injections after established retinal alterations. This evidence concerns the gene ADORA2A and diabetic retinopathy.